Accelerate to discover

Back to filter

Related topics

Magnetic resonance elastography techniques and preclinical applications

Bruker Biospin

Sep 14, 2021

It has been known for centuries that tissue stiffness can change in the presence of disease, but quantifying such...

See What's Possible with the PippinHT

Sage Science

Sep 14, 2021

Programmable DNA size selection enables new discoveries by helping optimize the library detected by a sequencer. That’s...

Ex Vivo dental imaging is directly translatable to the clinic

Bruker Biospin

Sep 14, 2021

Although patients are too large in size for preclinical microCT scanners, it still has a big significance in clinical...

IncuCyte live cell analysis system for 3D Organoids discovery

Sartorius & Essen BioScience

Sep 10, 2021

Live-Cell Analysis has revolutionized numerous studies, with a wide selection of applications namely 3D Tumour Spheroid...

Sep 20, 2021

Blood-Brain Barrier (BBB) - Pathophysiology in ischemic stroke

RWD

Aug 27, 2021

In-depth Understanding of Blood-Brain Barrier (BBB)

Introducing New Aura 4.0 software

Spectral Instruments Imaging

Aug 27, 2021

With new features for both acquisition & analysis Aura Software enables you to capture and analyze your data quickly,...

Micro-CT user meeting 2021

Bruker Biospin

Aug 19, 2021

Year after year, the Micro-CT User meeting showcases state-of-the-art applications in both life and material sciences,...

Sep 20, 2021

Comparison of gamma and x-ray irradiation results

Precision X-Ray

Aug 12, 2021

Biological effects of Cs-137 and X-ray irradiators are comparable with regards to reconstitution chimerism in normal...

Show all topics (10)

Mutual destruction of deep Lung tumor tissues by nanodrug‐conjugated and CQ1 imaging cytometer

Jun 1, 2018

The 10‐year survival rate of cancer patients has greatly increased over the last 20 years. However, the survival rate of patients with major malignant tumors, such as lung and pancreatic cancers, still shows negligible improvement.The conventional chemotherapeutic strategy for treating lung cancer remains unsatisfactory in this respect. Specifically, the 5‐year survival rates of both non‐small‐cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients exhibited merely 4–5% improvements in the past decade for cancer in stages I–III.2 The main difficulty in treating lung cancer is the lack of targeted chemotherapeutic agents specific to the lung tumor tissues and, thus, non‐specific targeting generally leads to unwanted side effects induced by excessive doses of chemotherapeutic agents.

Several strategies have been introduced to resolve the aforementioned issues, such as cancer antigen‐targeted monoclonal antibody (mAb) therapy,4 nanodrug delivery,5 and cell‐mediated therapy (i.e., T‐cell‐based therapy for NSCLC6). However, many clinical trials have shown that intravenously administered mAb, particularly epidermal growth factor receptor‐targeting mAbs, induced dermatological toxicities (e.g., acneiform eruption, xerosis, telangiectasia, hyperpigmentation, fissures, and hair/nail changes) in over 50% of patients after treatment.

Read more!

Scientific paper
Application

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Yokogawa

Yokogawa is a leading provider of confocal quantitative live cell imaging platforms. Combining superior technology with engineering services, project management, and maintenance, Yokogawa delivers field proven operational efficiency, safety, quality, and reliability. 

Related products

Confocal quantitative image cytometer CQ1 offers a new approach to image quantification

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey